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Abstract
Rapid scientific and technological advances have allowed for a more detailed understanding of the relevance of
intestinal microbiota, and the entire body-wide microbiome, to human health and well-being. Rodent studies have
provided suggestive evidence that probiotics (e.g. lactobacillus and bifidobacteria) can influence behavior. More
importantly, emerging clinical studies indicate that the administration of beneficial microbes, via supplementation
and/or fecal microbial transplant (FMT), can influence end-points related to mood state (glycemic control, oxidative
status, uremic toxins), brain function (functional magnetic resonance imaging fMRI), and mental outlook
(depression, anxiety). However, despite the advances in the area of gastro-biological psychiatry, it becomes clear
that there remains an urgent need to explore the value of beneficial microbes in controlled clinical investigations.
With the history explored in this series, it is fair to ask if we are now on the cusp of major clinical breakthroughs, or
are we merely in the quicksand of Autointoxication II?
Keywords: Intestinal microbiota, Autointoxication, Depression, Anxiety, Probiotics, Microbial ecology,
Lipopolysaccharide endotoxin, Diet, Intestinal permeability, MMP-9, Microbial ecosystems
Introduction
Though the first two parts of this series, we have
attempted to provide a historical and contextual approach
to the more direct lines of contemporary evidence as it
relates to gut microbiota, its intentional manipulation, and
mental health. Here in part III we will discuss more
specific research related to the direct experimental and
clinical effects of probiotics in the context of stress, neuro-
physiology, behavior and mental outlook. The emerging
studies clearly show that we are in the midst of a very
exciting time within gastro-biological psychiatry. Still, as
we conclude our series, it becomes evident that there
many unanswered questions and an urgent need for
expanded clinical investigations.
Experimental dysbiosis, stress and probiotics
More clinically relevant information related to behavior
is provided by animal studies involving interactions
between stress, dietary habits and alterations to the
normal homeostasis of gut microbiota (i.e. dysbiosis rather
than germ-free). The term dysbiosis is often erroneously
attributed to Metchnikoff, however, both eubiosis (healthy
life in steady state) and dysbiosis (shift from healthy state
of being) were already in popular use decades before
Metchnikoff gained fame. Physician Elliot E. Furney used
the terms together in his 1890 book related to plant,
animal and human resiliency [1]. In the context of intes-
tinal microbiology, dysbiosis is a term that gained medical
acceptance in the 1960s [2]. In animal models, researchers
can induce dysbiosis through experimental infection,
psychological stress, Western dietary habits, and/or the
administration of antimicrobial agents [3]. To date, the
emerging research shows that all of these factors may
interact together in a vicious cycle – i.e. in experimental
studies, induced states of dysbiosis can promote behavior
indicative of anxiety and cognitive dysfunction in animals
[3]. On the other hand, psychological stress itself leads to
dysbiosis [4,5], and it also encourages the consumption of
a fast-food-style diet [6], which only serves to further
promote dysbiosis [7]. * Correspondence: aclnd@cfs-fm.org
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dysbiosis invoked by small amounts of gut pathogens is
associated with increased markers of activation within
limbic structures of the brain (including the amygdala)
[8]. Intestinal vagal activity is also increased with patho-
genic dysbiosis, adding yet more evidence that the vagus
nerve is a primary portal of communication from in-
testinal microbiota upward toward the brain [9]. In-
duction of low-grade gastrointestinal inflammation
causes anxiety-like behavior in animals; however in
animals with a prior vagotomy, the behavior distur-
bances associated with gut inflammation were not
evident. Moreover, the oral administration of the pro-
biotic Bifidobacterium longum NCC3001 (Morinaga,
Japan) prevented the anxiety-like behavior associated
with gut inflammation in animals with an intact vagus
nerve, but it did not have this anxiolytic effect if the
vagotomy was performed after chronic low-grade in-
flammation. Remarkably, the reduction in anxiety-like
behavior after probiotic administration was not associ-
ated with any detectable reduction in gut inflammation
per se [10]. In other words, the vagus nerve appears to
be a conduit for behavioral change - anxiogenesis (via
gut inflammation) and anxiolysis (via the presence of a
probiotic). Separate research involving a strain of Lacto-
bacillus rhamnosus also showed that administration to
healthy animals in stressful situations reduced anxiety
and depression-like behaviors in the elevated plus maze
(EPM) and forced swim tests. These behavioral changes
were linked to alterations in the gamma-aminobutyric
acid (GABA) system of the brain in the probiotic group,
yet the changes in behavior and brain chemistry were
largely extinguished with vagotomy [11].
As we argued almost a decade ago regarding dep-
ression and the gut-brain axis, some species of intestinal
microbes can make significant contributions to the
prodcution of GABA and other neurotransmitters in vivo
[12]. The extent to which this local GABA intestinal pro-
duction can influence systemic physiology, depression and
anxiety remains a mystery [13]. For now, we do know
through preliminary research that the oral administration
of GABA derived from Lactobacillus hilgardii fermenta-
tion has been shown to have clinical value in anxiety re-
duction [14]. As for vagus communication, the vagal
innervations of the intestinal tract are rich in the small in-
testine, with relatively fewer in fibers extending into the
large intestine. Therefore it is also noteworthy that other
studies have shown that prior vagotomy does not always
prevent anxiety-like behavior in the presence of gut patho-
gens [15]. This suggests that there are multiple lines of
communication between the intestinal tract and brain.
Indeed, the administration of Bifidobacterium longum
normalized anxiety-like behavior and hippocampal BDNF
levels among animals when the parasite Trichuris muris
was introduced orally – the behavioral benefits were once
again independent of inflammatory cytokines [15].
As described in Part I, Lloyd Arnold reported in the
1920-30s that dietary context can influence intestinal-
pathogen-induced symptoms and mortality. Remarkably,
he found that the standard stock rodent chow, one that
they had been using for years in his lab to raise mice,
was associated with the highest mortality in mice upon
Salmonella enteritides exposure vs. other natural foods.
In particular, a switch from the standard chow to banana
powder decreased mortality from 96% to 6% over one
month post-infection [16]. For Arnold, the food vehicle
was an important factor in intestinal microbiology out-
comes. Although he did not determine it at the time,
modern research shows the banana to promote the
growth of bifidobacterium [17]. When contemporary
researchers added 97% lean meat to the standard diet of
rodents for 3 months they found an increase in the
diversity of the intestinal microbiota, as well as de-
creased behavioral signs of anxiety and improved aspects
of cognition [18]. From the experience of Arnold, we
cannot assume that the “standard” lab chow is the
default healthy fare. Although this type of research on
meat added to standard fare establishes correlation and
not causation, it should provide a stimulus to more
closely examine the potential links between Paleolithic
nutrition, of which lean meat was a significant part, its
reported health benefits [19], and the diversity of the
intestinal microbiota.
Of course, this research also exposes the short-comings
of the term dysbiosis, in that a shift from ‘normal’ homeo-
stasis of intestinal microbiota (via a better quality diet)
might actually confer benefit to the host. The same is true
of antimicrobial administration – clearly, antimicrobial
agents can cause massive shifts in gut microbiota, yet here
again the oral administration of these agents to mice (anx-
ious BALB/c strain) caused a decrease in anxiety-like
behavior. Such was not the case when the antimicrobial
agents were delivered by injection, nor were there any
behavioral changes when the agents were delivered orally
to germ-free mice [20]. As mentioned, the regular
consumption of a high-fat diet causes alterations in the
characteristics of the intestinal microbiota, yet when anti-
microbials are administered along with the Western-style
diet, the detrimental diet-induced effects on systemic
inflammation, systemic LPS burden and glucose-insulin
dysregulation are minimized [21].
It is unlikely that antibiotics are a long-term solution to
depression; however, the recently reported success of
minocycline in depression [22] can no longer be theorized
to simply be a matter of the direct neuroprotective proper-
ties of the agent. Together, the combination of minocycline
and probiotic (E. coli Nissle 1917) is more effective at redu-
cing experimental intestinal inflammation and markers of
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this combination of probiotic and antibiotic significantly
reduced the expression of matrix metalloproteinase 9
(MMP-9) [23], a salient finding given the emerging re-
search suggesting that increased MMP-9 activity is associ-
ated with loss of intestinal microbiota diversity. In the
period following a challenge with pathogenic intestinal mi-
crobes, MMP-9 knockout mice show an increase in lacto-
bacilli [24], meanwhile increased MMP-9 activity is
associated with intestinal permeability [25,26], and the se-
verity of human depression [27-29]. Since consumption of
the Mediterranean diet is associated with decreased
MMP-9 activity [30], researchers must once again attempt
to decipher the extent to which dietary benefits might be
intertwined with intestinal microbiota. When a multi-strain
probiotic is consumed with a high fat (predominantly corn
oil) diet, the elevations of MMP-9 and systemic oxidative
stress is minimized [31].
Alvarez revisited, again
Some of the more intriguing animal studies in recent
years have involved the efficacy of probiotics in the
reduction of visceral pain, including that related to colo-
rectal distention. One study involved 9 days of probiotic
supplementation (Lactobacillus reuteri vs. control) prior
to experimental colorectal distension in rats. Remark-
ably, live probiotic prevented the physiological signs of
visceral pain (marked bradycardia) that was otherwise
evident in the control group. The researchers found the
same effect whether or not the L. reuteri was alive, heat
or radiation-killed, indicating that even structural com-
ponents of probiotics can play a role in visceral sensiti-
vity. This reduction in cardio-autonomic response in the
animals was noted even at the highest level of distention
pressure (80mm Hg), and the resiliency was accompan-
ied by an inhibitory effect on discharge of colonic affer-
ent nerve fibers in the probiotic groups [32]. Separate
research has found that the oral administration of
Bifidobacterium infantis 35624 can reduce visceral pain
behaviors in both normosensitive and hypersensitive-
anxious rat strains during colorectal distention [33]. The
same strain of Bifidobacterium infantis can normalize
sensitivity to colorectal distention in a rat model of post-
inflammatory colonic hypersensitivity [34]. Moreover,
Bifidobacterium lactis CNCM I-2494 in a fermented
dairy matrix has been shown to reduce visceral hyper-
sensitivity when colorectal distention occurred in the
context of psychological stress. This study also showed
that the probiotic reduced intestinal permeability and
blood endotoxin levels. It is noteworthy that the anti-
nociceptive effect of the fermented dairy product (inclu-
sive of the aforementioned bifidobacterium strain plus
Lactococcus lactis and two yogurt starters L. bulgaricus
and S. thermophilus) was more effective than an equivalent
dose of Bifidobacterium lactis CNCM I-2494 alone [35].
Here we see the relevance of the often overlooked interplay
of beneficial microbial synergy and the context of the food
matrix.
Lactobacillus farciminis has also been shown to abo-
lish colorectal distension hyeralgesia in an animal model
of acute stress. Indeed, the expression of Fos, a marker
of general neuronal activation, was activated in limbic
pathways (paraventricular nucleus of the hypothalamus,
medial nucleus of the amygdala) by colorectal distention –
however, L. farciminis administration significantly reduced
Fos expression in these areas during colorectal distention
[36]. Finally, researchers have also shown that antibiotic-
induced shifts in intestinal microbiota increases visceral
hyperalgesia in healthy mice, and that the administration
of Lactobacillus paracasei NCC2461 prevented this
antibiotic-induced visceral sensitivity [37]. Importantly,
the administration of L. paracasei did not restore normal
lactobacilli levels overall, indicating that a major influence
on gut microbial genera is not required for therapeutic
efficacy via probiotics.
Although these are preliminary animal studies, one
cannot help but to reconsider the influential voice of
intestinal toxemia’s most vehement critic. Recall from Part
I that Alvarez, who focused his attention on Freudian-
inspired conditions - ‘hysterical’ bloating and ‘neurosis of
the abdominal wall’ as he called them - claimed that per-
sonal (non-immune, non-microbial) sensitivity to disten-
tion was at the heart of the gastrointestinal complaints in
many of those with neurasthenia. Alvarez turned out to be
correct in proposing a psycho-mechanical theory, his 1919
assertion [38] that ‘in sensitive people the brain is pro-
foundly influenced by afferent impulses coming from a
distended, underactive or unduly active bowel’–certainly
modern day interoseptive sensitivity in anxiety and pain-
related conditions would support this notion [39,40].
However, microbes and their breakdown products, their
local and systemic effects in mental outlook and pain, are
clearly emerging as part of the equation. Could microbes
be a bottom-up player in that personal sensitivity? Might
microbes be responsible for neurosis of gut linings and
hysterical bloating? The above research on probiotics and
colorectal distention will force scientists to explore alter-
native research pathways.
Consider the separate research on methane producing
microbes within the intestines; these microbes have been
consistently linked to constipation [41-43], and are now
thought to directly mediate motility via methane pro-
duction [44]. Recent investigations demonstrating small
intestinal bacterial overgrowth (SIBO) and excess methane
production in children with encopresis might suggest that
the condition may not be exclusively psychogenic [45].
Constipation is 5 times more likely in children with the
related condition of nocturnal enuresis [46], and intestinal
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enuresis in children [47]. As lines of investigation become
integrated, it may be worth examining how might
probiotics mediate pain and childhood behavioral disorders
via their interaction with methane-producing and other
living intestinal residents.
Putrefactive chemicals – still an open question
A primary focus among the scientists and clinicians of
the autointoxication era was on gut-derived putrefactive
chemicals and their burden on the brain and elsewhere.
As autointoxication faded away, Alvarez and others
dismissed the notion that, except under rare circum-
stances, these chemicals could be absorbed and/or
retained at any appreciable levels such that they could
influence health. Although the modern gut-to-brain
scientific focus has shifted to LPS and inflammatory
cytokines, even the classic putrefactive chemicals (e.g.
putrescine, spermidine) and some of the gut-derived and
liver metabolized/conjugated structures (e.g. indoxyl sulfate,
p-cresylsulfate, known classically as “ethereal sulphates”)
continue to be linked to systemic cellular damage and
neuropsychiatric disorders [48-52]. In particular, indoxyl
sulfate, p-cresylsulfate and other uremic toxins are the sub-
ject of renewed interest as being a potential link between
k i d n e yd i s e a s ea n dt h es e v e r i t yo fd e p r e s s i v es y m p t o m s .
Decline in renal functioning has been consistently linked to
cognitive decline and depressive symptoms. Since the kid-
neys are tasked with the removal of these toxins generated
by colonic microbes, eliminating them via urine, it was long
held that any major toxic concerns would be restricted to
the later stages of chronic kidney disease.
Although the association between cardiovascular disease
and kidney disease is clearly significant, uremic toxins are
presenting themselves as independent predictors of CVD
risk, even at surprisingly mild levels of kidney disease.
Recent studies show that even mild increases in serum
p-cresylsulfate (0.7mg/L) are associated with coronary
artery disease [53], and experimental studies show that
p-cresylsulfate causes inflammation and damage to blood
vessels [54]. Moreover, experimental studies using a model
of depression shows cellular damage in the renal system
subsequent to psychological stress [55], meanwhile,
depressive symptoms and stress have been linked to a
compromise in human kidney filtration [56]. Since uremic
toxins themselves can compromise kidney function, any
increased burden in the load of such chemicals over a
prolonged period may have profound implications in
setting up a viscous cycle [57].
In animals, uremic chemicals can influence neuro-
transmitter levels in the brain, and emerging studies
suggest they may have divergent effects on behavior
depending on the level of production – in other words,
too little or too much of these gut-derived chemicals
may influence behavior [58]. Isatin, a chemical with
similar structure to indoxyl sulfate provides an example.
Compared to germ-free animals, urinary output of isatin
is 50-fold higher in animals with conventional micro-
biota [59]. Studies show that isatin can, depending on
the level, have a divergent influence on appetite, anxiety,
sedation and serotonin levels in the animal brain [60].
Administration of large doses of isatin (200 mg/kg) cause
a delayed increase in intestinal alkaline phosphatase
(IAP) [61], suggesting it may have an influence on sys-
temic LPS burden. Consider that a recent study indicates
that there may be dozens of these biologically active
colon-microbe-derived uremic solutes that remain un-
identified [62]. New technologies are not only providing
for proper identification, they are also allowing scientists
to make previously overlooked connections between
such chemicals and systemic health [63]. How these and
other gut-derived chemicals might influence mental
health in the context of intestinal permeability, a more
porous blood–brain barrier, and low-normal kidney
filtration, remains, incredibly, after the passage of a
century, an open question. The antiquated urinary indican
test has been replaced by profiles of urinary proteomes
and metabolomic databases [64]. The extent to which
probiotics and a well-diversified diet (rich in plant foods
and fiber) can influence intestinal microbial ecology, the
burden of putrefactive chemicals and uremic toxins, is an
ongoing area of research [65,66]. The role of the liver in
the metabolism of circulating putrefactive chemicals is yet
another related issue.
Additional experimental avenues
Meanwhile, other lines of experimental research con-
tinue to highlight the utility of probiotics in the preven-
tion of intestinal permeability [67], reduction in systemic
oxidative stress (inflammation and LPS load) [68,69],
and in the support of nutritional pathways for optimal
neurotransmitter functioning. For example, the oral
administration of probiotics via laboratory chow has
been shown to increase peripheral tryptophan levels
[70], plasma and brain docosahexaenoic acid (DHA)
levels [71,72], as well as alter serotonin and dopamine
turnover in the frontal cortex and limbic system [70].
Oral probiotics appear to increase resiliency of nerve
cells and reduce apoptosis during conditions of experi-
mental physiological stress [73]. Additional research has
emerged indicating that Lactobacillus plantarum C29, iso-
lated from the traditional Asian food kimchi, can increase
hippocampal brain derived neurotrophic factor (BDNF)
[74]. Numerous reports indicate low BDNF levels in de-
pression, and its administration in experimental models
improves depressive-like behavior [75]. In experimental
models of psychological stress, oral bifidobacteria reduces
systemic inflammatory cytokines and normalizes brain
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manipulating the diet of animals such as to double the
fecal lactobacillus counts, results in decreased anxiety-like
behavior [18,76,77]. In an animal model of chronic fatigue
(28 day exposure to forced swim test), the administration
of L. acidophilus (vs. placebo) reduced immobility and
observations of post-swim fatigue – these effects of
L. acidophilus were in tandem with reductions in brain
measurements of oxidative stress and serum measure-
ments of the inflammatory cytokine TNFα [78]. Recently
it was reported that in addition to systemic protection
against lipid peroxidation, oral Bifidobacterium animalis
01, isolated from centarians, decreased oxidative stress
burden and brain monoamine oxidase activity, thereby
potentially increasing neurotransmitter levels between
synapses [79].
The influence of probiotics as a means to attenuate
substance P release may also play a relevant role within
the gut-brain connection. Experimental alterations to
the normal gut microbiota can increase substance P
release in the nervous system and promote behaviors
reflective of anxiety [80]. Indeed, even very slight eleva-
tions in circulating substance P can lead to anxiety,
depression and aggression [81]. Conversely, those who
respond to antidepressant pharmacotherapy are known
to have declines in serum substance P in conjunction
with improved mood states [82]. An additional area of
relevance between emerging probiotic research and
depression/anxiety involves the cannabinoid receptors.
Recent studies suggest that cannabinoid receptor-2 (CB-2)
agonists have anxiolytic and anti-depressant properties
[83]; these CB-2 agonists also limit substance P produc-
tion [84] and prevent LPS-induced blood–brain barrier
permeability [85]. These findings take on greater meaning
given the preliminary findings regarding the ability of
probiotic strains to enhance CB-2 expression [86].
Researchers have begun to explore the crosstalk
biomarkers through which microbiota and host commu-
nicate. For example, Lactobacillus plantarum has been
shown to secrete bioactive extracellular proteins capable
of interacting with and modulating dendritic cells [87].
The secretion of peptides by lactobacilli, their displace-
ment abilities relative to even minute levels of anxiety-
provoking gut pathogens (e.g. C. jejuni as previously
described) continue to be demoinstrated [88]. As resear-
chers grapple with developmental origins of health and
disease (DOHaD) [89], it is becoming clear that one
important consideration may be the interaction between
maternal/early life stress and the intestinal microbiota.
Early life stress in animals appears to produce a more
dramatic alteration to gut microbiota when acute stress
is subsequently experienced in adulthood [90]. The role
of neonatal exposure to probiotics in reducing the
impact of subsequent adult stress on gut microbiota has
recently been reported, however the extent to which this
may influence behavior remains an open question [90].
In a study which takes us back to the previously
described work of Fenton Turck in 1916 [91,92], a
French group have recently reported that after one week
of a high-fat diet, prior to full onset type 2 diabetes (or
the animal model thereof), live commensal bacteria are
found in the blood and adipose tissue where they are as-
sociated with low-grade inflammation [93]. The 6-week
administration of Bifidobacterium animalis subsp. lactis
420 to these animals reversed the bacterial translocation,
its associated adipose tissue inflammation and metabolic
disturbances indicative of diabetes [93]. Of course, as de-
scribed in Part I, these are the types of findings that were
discussed, and subsequently scoffed at, during and after
the halcyon days of intestinal toxemia/autointoxication.
Finally, with regard to the prevention of psychological
stress-induced intestinal permeability and endotoxemia,
a recent study has shown that oral L. farciminis can re-
duce the effects of this vicious cycle in an animal model
of acute stress [67]. Specifically, probiotic administration
for 2 weeks suppressed the intestinal permeability and
systemic LPS burden otherwise produced by restraint
stress. Importantly, this protective quality was, in turn,
associated with an attenuated hypothalamic-pituitary-
adrenal (HPA) axis response and a reduction in central
neuroinflammation [67]. The results suggest that, be-
yond direct vagal communications, the potential benefits
of probiotics in mental and cognitive health, at least
among some strains, may be a by-product of their ability
to protect the gut lining during stress.
Relevant clinical investigations
Recently there has been, once again, a suggestion that it
might be possible to vaccinate against depression [94].
Specifically, researchers involved in a lung cancer trial
using intradermally-injected heat-killed Mycobacterium
vaccae took note of its unexpected improvement in
quality of life scores. Although it did not alter cancer
survival times, benefits in favor of M. vaccae injections
included aspects of cognition, vitality, and emotional
health. [95] Of course, this is reminiscent of Satterlee’s
extensive writings on the use of gut microbe-derived,
intradermally-injected vaccines for mental health, in-
cluding his previously mentioned techniques published
in JAMA [96]. It is noteworthy that M. vaccae is widely
distributed in nature, including soil and water, and it
begs the question to what extent is the withdrawal from
contact with nature and its non-pathogenic microbes a
factor in mental health? As mentioned, it has been re-
cognized for over a century that lactobacilli can be found
in garden soil and on plant foods [97]. Recent investiga-
tions have shown that bifidobacterium spp are also
found in the soil, indeed this genera can survive in soil
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[98]. Very preliminary findings in animal studies show
that heat-killed M. vaccae can beneficially influence
brain serotonergic activity under stress, and live M. vaccae
added to the mice diet improves behavioral displays of
anxiety and cognitive functioning [99]. These studies indi-
cate that a closer examination of injectable immune-
modulating microbes for mental health seems warranted;
indeed, as discussed later we may be forced to redefine
the very term probiotic.
Human research continues to accumulate in the area
of probiotics and oxidative stress. A 6-week study
involving patients with type 2 diabetes showed that
probiotic yogurt administration improved fasting blood
glucose as well as systemic antioxidant enzyme activity
and total antioxidant status [100]. In a one-month
study, the administration of L. rhamnosus IMC 501 and
L. paracasei IMC 502 minimized the systemic oxidative
stress, lipid peroxidation in particular, associated with
intense physical activity [101]. Given the documented
associations between lipid peroxidation, glycemic vari-
ability and mood [102], the results are of relevance to
mental health research. Moreover, a clinical study has
also demonstrated the value of probiotics (L. casei, L.
plantarum, B. brevis) in the treatment of SIBO, indeed
the pilot study (n =50) showed a more favorable
response to probiotic treatment vs. the metronidazol
control [103].
There has also been intriguing preliminary research
involving probiotic administration and changes in the
brain activity as measured via functional magnetic reson-
ance imaging (fMRI). In a double-blind, controlled study,
45 healthy women (age 18–50) consumed either a pro-
biotic yogurt (Bifidobacterium lactis CNCM I-2494, L.
bulgaricus and L. lactis) vs. non-fermented dairy vs. no
beverage for one month. The fMRI was conducted dur-
ing an emotional reactivity task (viewing faces displaying
a negative emotional reaction vs. viewing shapes). Based
on blood flow assessments during the task, the probiotic
group showed diminished activity in the mid/posterior
insula vs. the control groups [104]. While preliminary,
the results suggest that orally administered probiotics
can alter brain activity in regions involved in receiving
signals from the gut and the ultimate level of subsequent
emotional arousal.
Fecal microbiota transplantation
Finally, although not probiotics per se, a consideration of
fecal transplant materials is worth mention. By the
current definition, a range of live commensal bacteria
from a healthy adult as used in fecal microbiota trans-
plants (infusions), should they confer benefit, could be
considered a probiotic blend of sorts. Infusion of fecal
microbiota from healthy donors has recently been
reported to improve insulin sensitivity in individuals with
metabolic syndrome, [105] and neurological symptoms in
cases of multiple sclerosis [106]. Working in reverse order,
a recent case report shows major weight reduction when
the opportunistic pathogen Enterobacter cloacae B29 was
eradicated from an obese adult, and remarkably, the in-
duction of obesity, inflammation and serum endotoxemia
when that same strain was introduced to gnotobiotic mice
[107]. The encouraging but very preliminary findings
using fecal microbiota transplantation (FMT) will likely
change the investigative path in the search for the Rosetta
Stone – i.e. that which specifically defines the ideal fecal
microbial (healthy donor) profile, including specific gen-
era/species/strains, that could ultimately confer long-
lasting benefit to its new host. In the meantime, a recent
randomized clinical trial of L. reuteri ATCC55730 showed
that the strain reduced mucosal inflammatory cytokine
production after it was administered as a rectal enema for
8 weeks [108].
While some researchers continue to search for specific
probiotic strains as transfer candidates, others are examin-
ing the use of cocktails of pathogen-free microbes derived
from the entire commensal range [109]. Experimentally, in
highly sensitive/anxious mice (BALB/c), the colonization
of microbiota derived from more explorative NIH Swiss
mice changed the BALB/c mice behavior – the typically
a n x i o u sB A L B / cm i c eb e c a m em o r ee x p l o r a t i v e .T h e
opposite occurred when NIH Swiss mice were colonized
with the BALB/c micro biota [110]. It seems only a
matter of time before FMT will be examined in those
with mood and behavioral disorders where GI symptoms
are present – we need no fresh hypotheses or theories to
justify an attempt.
Direct clinical investigations
The first formal investigation of the potential psycho-
logical benefits of strictly defined probiotic supplementa-
tion in humans involved 132 otherwise healthy adults;
those who had more depressive symptoms at baseline
had significant improvement in mood scores after taking
a probiotic Lactobacillus casei fermented beverage com-
pared to the placebo group [111]. A separate placebo-
controlled pilot study involved 39 chronic fatigue
syndrome patients who were administered the same oral
Lactobacillus casei probiotic vs. placebo. At the conclu-
sion of the 8-week study, depression scores remained
unchanged between the groups, however there were
significant improvements in anxiety as measured via the
Beck Anxiety Inventory vs. placebo [112].
Even more recently, French researchers evaluated a
Lactobacillus helveticus and Bifidobacterium longum com-
bination probiotic which was orally administered for one
month in a placebo-controlled study. Using a variety of
validated anxiety, stress, and depression scales, researchers
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sion, anger, anxiety, as well as lower levels of the stress
hormone cortisol among otherwise healthy adults taking a
daily probiotic supplement vs. placebo. In addition, an
experimental arm of this study also confirmed that the
probiotic added to the chow of rats did indeed decrease
behaviors indicative of anxiety [113]. Moreover, given
the above-mentioned study linking baseline depressive
symptoms and improved mental outlook among healthy
adults after probiotic administration, the French group
performed a secondary analysis looking specifically at
those with the lowest baseline urinary free cortisol (n=25).
Indeed, the results once again showed improvement with
Lactobacillus helveticus and Bifidobacterium longum vs.
controls (particularly in somatization, depression and
anger-hostility), and among this low cortisol sub-group the
overall benefits in anxiety and depression were pronounced
over time [114]. Finally, in a study involving 44 patients
with irritable bowel syndrome, the oral consumption of a
prebiotic fiber (trans-galactooligosaccharide) significantly
reduced anxiety in conjunction with marked elevations in
fecal bifidobacteria levels [115].
Conclusions and future directions
Looking back at the first three decades of the 20th
century is an experience, for the modern scientist inter-
ested in the gut-microbiome-brain connection, akin to
an anthropological archeologist discovering an ancient
civilization. Superficially, the historical markings are
dominated, as they often are in medicine, by the myopic
and biased view toward the so-called ‘great/infamous
men, great/infamous discoveries and claims’. Medical
historians focus on heroes and anti-heroes in the fights
against ignorance and disease. Yet the complete chroni-
cles are never as simple as Lane vs. Alvarez. Psychiatrist
and medical historian Iago Galdston warned against
losing context and understanding with such chronicles -
‘The essential deficiencies in academic medical history
derive from its commitment to the “great man, great
discoveries” view of medical history and of medical
progress...those who labour long at such gathering are
prone to mistake their miscellany of accumulations for
real knowledge and deep understanding’ [116]. Sifting
through the archives, moving past the outer walls of
intestinal autointoxication dominated by Metchnikoff,
Lane, Cotton and non-physician opportunists, one finds
rational works that were in line with modern-day
‘discoveries’ - antecedents to what we are now, in many
ways, relearning and constructing related to the impor-
tance of the gut integrity and its microbial residents. An
examination of the early history of oral bacteriotherapy
reveals hundreds of studies dedicated to the intestinal flora
and its transformation. Although many of these studies
reported conflicting findings, and the methodologies were
most certainly based on rudimentary technique by the
standards of today, there were more than enough clues
to suggest that the primary premise – i.e. gut-derived
microbes and/or microbial breakdown products may
play a role in mental health – was correct.
Related concerns of intestinal permeability, SIBO,
hypochlorhydria, carbohydrate intolerance, endotoxins,
modernity and dietary matters, gut microbe vaccines,
the oral administration of lactic acid bacteria, colonic
microbiota transfer, and qualitative/quantitative changes
to the intestinal microbiota were all discussed as being
relevant to mental health and cognition. For a variety of
reasons, not the least of which included lack of human
evidence and broad claims that autointoxication was the
exclusive root of all neuropsychiatric disorders, these
discussions disappeared from mental health publications.
One cannot say that the disappearance of autointoxication
was driven exclusively by the emergence of evidence-
based medicine because in many cases it would be
supplanted by unverifiable Freudian psychoanalytic view-
points. Still, clinicians pleaded for more than studies in
rodents, rabbits and monkeys – they needed convincing
human research so that medicine could be practiced not
by hypothesis - and yet none would be forthcoming.
Unwarranted colectomies and unfounded marketing pro-
missory notes for good health via friendly microbes would
obscure legitimate research pathways that might have
otherwise been followed with vigor. They also created a
superficial and simplified medical history based on great
or infamous men. Over time, autointoxication would
become known only for these surgical and marketing
extremes, ultimately becoming a medical outcast – or, as
it was written just prior to our hypotheses papers, ‘a
triumph of ignorance over science’. Yet, as the French
physiologist Claude Bernard wrote, “That which we know
is a great hindrance to our learning that which is yet
unknown to us”. By the year 2000 we “knew” intestinal
toxemia and friendly microbes for mental health to be
exclusively a medical folly, one associated with charlatans
and so-called colon cleansers.
All of this contemporary work, as described above,
forces us to have a fresh look at the inner dialogue within
the historical intestinal toxemia publications. Obviously
the modern advances are not a validation of colectomy,
L. bulgaricus as a fountain of youth, or colon cleansers
as a solution to all the potential ills of what may indeed be
a type of intestinal ‘toxemia’. However, modern historical
reviews that stick exclusively to the redundant and super-
ficial narrative of “autointoxication was the arena of
charlatans, it was wrong and disproven by Alvarez”
contribute little, and indeed provide a disservice to the
medical minds that were on a rational path. Of course,
reminders of the dangers of practicing medicine by
hypothesis alone have their place. However, it may be
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that of those who found that a high fat diet and stress in-
creased intestinal permeability and bacterial translocation,
or those who reported successful outcomes with simple
fecal transplantation. Why should the legacy of those who
instilled fears into healthy adults regarding autointoxica-
tion, as a means to sell pseudoscientific contraptions, ob-
scure that of rational physicians who saw some legitimacy
to intestinal toxemia as relevant to unhealthy popula-
tions? It is fairly obvious many of those physicians ration-
ally discussing intestinal toxemia a century ago were
confronted with unhealthy patients (IBS, ME, FM, mi-
graine, mood and anxiety disorders) that would today be
classified with elaborate diagnostic criteria and codes.
Top-down, psychosomatic-oriented theorists [117]
continue to haul out Lane and Cotton as exhibits A and
B to exclaim that autointoxication as it relates to mental
health was nonsense [118] - with nary a mention of the
history of the other not-so-Great Men, and the emerging
gut-brain-microbiome research. Psychosomatic resear-
chers continue in their quest to show that IBS is pro-
voked by neuroticism – non-prospective, x-sectional
population studies show high degrees of neuroticism
correlate with IBS severity, and the Pubmed abstracts
boldly conclude that ‘These results suggest that neuroti-
cism is involved in the pathophysiology of IBS’ [119].
These strong assertions are accompanied by nary a men-
tion of gut microbiota. What if it were the opposite?
What if the bottom-up microbiota is involved in the
provocation of neuroticism among IBS patients? Or
what if, as is more likely the case, it lays somewhere in
the middle ground? Once again, psychiatrist and histo-
rian Iago Galdston, provided advice for research and
direction (in 1954) of what he hoped would be a new era
in psychosomatic medicine, one without labels of “type”
(e.g. Alvarez’s go-getter “ulcer” type etc.) as they pertain
to disease. He advised a shift to the middle ground –‘ we
will learn to understand the experiences of man in terms
of multidirectional relations, and with a simultaneity
that is free of the naiveté and artificiality of straight line
sequential causality...when we have come to such an
understanding, psychosomatic medicine will be truly
holistic. But then, may I whisper it softly, it will no longer
be psychosomatic medicine. It will be medicine such as
Hippocrates could comprehend, and Paracelsus might
celebrate – a keen reflection on the interrelations of
Microcosm and Macrocosm’ [120].
With all our modern advances, we once again arrive at
a place of theory, albeit slightly more sound in its support.
In order to truly advance from the days of Metchnikoff we
must expand the bench and rodent work and bring it into
the clinical investigative setting, and not to do so, of
course, for the purpose of yet more anecdote. The
undoing of intestinal toxemia and the idea of probiotics
for brain health was not Alvarez, it wasn’t the charlatans
and the high colonics, nor was it for the want of more ro-
dent and laboratory studies - its undoing was the lack of
convincing controlled clinical work. It seems remarkable,
given the supporting scientific rationale, that there has
been so little in the way of clinical research. At this point,
as highlighted throughout this series, we already have
extensive experimental research from which to guide pro-
biotic strain selection for clinical experimentation – e.g.
strains that can lower LPS burden; strains that lower
oxidative stress, and systemic inflammatory cytokines;
strains that have a beneficial influence on stress resiliency;
strains that can influence neurotransmitter precursor
levels via amino acids and neuronal membrane structure
via fatty acids; strains that can attenuate intestinal perme-
ability; strains that can lower uremic toxin burden. It may
take decades to further elucidate the divergent ways in
which these and other specific probiotic strains may inter-
act, alone and in combination with each other, to influ-
ence markers relevant to animal models of depression
and/or anxiety. This critical work should, of course, con-
tinue. However, the mouse models will always be lacking
the clinically-relevant context of mood-related diet, phy-
sical activity, environmental toxin exposure and other
variables within lifestyle medicine. Probiotics, even if they
do influence the human GABA system, are not synthetic
benzodiazepines; as discussed throughout this paper,
orally administered microbes are much more likely to
converge with lifestyle variables within the gut lumen.
This presents a quandary for experimental researchers
examining the use of probiotics in the behavior of ani-
mals as a means to inform clinical utility. Since environ-
mental enrichment factors are known to interact with
psychological stress and diet, both of which interact with
gut microbiota, a near-endless combination of animal
housing and dietary variables related to microbes must
be investigated - from running wheels, tunnel position-
ing, wood, plastic and soil materials [121-123]. To put it
more clearly, a high-fat diet can compromise brain func-
tion as previously described, however, the detrimental
cognitive effects of too much fat can be significantly
offset by the degree of naturalistic environment [124] in
which the animals reside! Could there be probiotic
strains that might appear to be without value in one
model, yet provide value when interacting with environ-
mental variables such as physical activity? As for diet
itself, a multitude of dietary variables could potentially
interact with probiotic administration in animal beha-
vioral studies. The potential value of a specific strain or
groups of strains of probiotics may be dependent, or put
another way, may be obscured, by a host of dietary vari-
ables. Despite more than ample scientific justification,
only our own group [112] and a few others have begun
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mood, cognition and fatigue. The results from these
early studies, in concert with what is now a fairly robust
body of experimental research, would suggest that we
have now passed the time in which clinical investigations
should be approached with vigor. Moreover, the work of
Michaël Messaoudi [113,114] and colleagues from France
deserve special accolades, for this group has been simul-
taneously sampling the effects of probiotcs on behavior in
animal models and mental health in clinical settings.
Human intervention studies with probiotics related to
allergy risk, including prenatal/early life administration,
have been ongoing for more than a decade – perhaps it is
time for neuropsychiatric researchers to catch up.
The strain specific focus is clearly justifiable in the sci-
entific examination of a particular probiotic preparation
or commercial ‘functional food’ for mental health.
Research not only shows that heat-killed bacteria may
have strain-specific benefit, the research also indicates
that there are broad and divergent effects of lactic acid
bacteria in their interaction with the immune system
[125]. If we isolate single strains, we should indeed have
a good degree of certainty that its potential influence is
that which is desired in immune function over the long
term. Less known is the extent to which an individual
strain might influence the overall microbial ecology of
the gut when consumed for extended periods of time.
Could a single strain diminish diversity? The isolated
strain approach also carries a less speculative caveat; it
tells us little about the potential synergistic benefits of
multi-species lactic acid and other bacterium found in
traditional diets and fermented foods. Are we obscuring
microbial benefits with a myopic view to single patented
and/or commercial strain? Beneficial microbes are abun-
dant in indigenous diets, and an estimated 35% of all
lactic acid bacteria isolated from raw fruits and vegetables
can survive gastric conditions [126]. Beyond lactic acid
bacteria we can consider the previously mentioned studies
on live M. vaccae added to the dietary of animals – as a
soil-derived organism, M. vaccae can easily find its way
onto plant foods. It seems the links between traditional
dietary patterns, mental health and microbiota, are far
more complex than generally appreciated. We simply can-
not view the gut-brain-microbiota axis as isolated from
diet, the context of its macro and micronutrient as well
as phytochemical composition. This fact underscores
the potential futility of probiotic administration to a
sedentary individual with depression that may be co-
consuming a fast-food style diet with the addition of
pharmaceuticals and/or dietary chemicals (e.g. sucralose)
that are otherwise capable of altering the intestinal micro-
biota [127]. These are just some of the clinical realities not
addressed in simple experiments with rodents in an
elevated plus maze.
Have we advanced, will we advance?
In the real-world of mental healthcare provider and
patient, one that occurs in a holistic setting involving
lifestyle factors, the odds of a single strain of probiotic
bacterium providing clinically meaningful and long-
lasting benefit, not simply statistically significant differ-
ences vs. placebo, could not be estimated to be high.
Yet, probiotic experiments with rodents, just as they did
in the day of Metchnikoff (“Yoghurt – the anti-toxin of
old age” May, 1913) [128], generate headlines such as
“Forget Prozac – Try Probiotics” (Sept 10, 2012) [129].
Widely disseminated inferences that, based on current
rodent research, probiotics are a substitute for fluoxetine
are not only alarming, such headlines should ultimately
force us to ponder to what extent we have truly
advanced from Metchnikoff.
Today, in the new era of Autointoxication II, what is old
is new again – preliminary non-clinical research efforts,
based on metagenomics and microbiome projects, are
commercially co-opted to support a financially lucrative
probiotic business wherein unsubstantiated claims abound
[130]. Metchnikoff’s history is repeating itself - in a 2011
study published in PLoS One, Japanese researchers showed
that a strain of Bifidobacterium animalis can increase lon-
gevity in mice via its influence on gut polyamine produc-
tion [131]. In 2012 researchers linked negative mood,
social anxiety and distressed personality type, if you can
imagine, to indoxyl sulfate levels in a healthy (n =1502)
p o p u l a t i o n[ 1 3 2 ] ;m e a n w h i l e ,i no t h e rn e w s ,t h e r ea r e
now commercially available probiotic formulas in North
America that are clearly positioned, in their direct product
names and associated claims, as anti-aging and anti-stress
formulas [130]. It seems fair to ask, at this juncture, when
will this research pathway truly enter and emerge from
phase I of translational medicine? Will all of this work
become another clinically meaningless forgotten city in
the future, one destined to once again be explained away
by conflicts over toilet training? If there is a future role of
probiotics in cognitive and mental health, one relevant for
clinicians, and one that can only be proven or disproven
by human intervention studies, it is almost certainly as
our group hypothesized it to be – an adjuvant to well-
established first-line care.
Competing interests
ACB and EMS have no competing interests. ACL has received consulting fees
from Genuine Health, Toronto, Canada.
Authors’ contributions
ACB, ACL and EMS contributed equal time and effort in the investigation,
research and drafting of this manuscript. All authors read and approved the
final manuscript.
Author details
1Complex Chronic Diseases Program, BC Women’s Hospital and Health
Centre, B223A-4500 Oak Street, Vancouver, BC V6H 3N1, Canada.
2CAMNR,
775 Blithedale Avenue Suite 364, Mill Valley, CA 94941, USA.
3Harvard
Bested et al. Gut Pathogens 2013, 5:4 Page 9 of 13
http://www.gutpathogens.com/content/5/1/4Medical School and Massachusetts General Hospital, 40 Crescent St., Suite
201, Waltham, MA 02453, USA.
Received: 7 February 2013 Accepted: 10 March 2013
Published: 16 March 2013
References
1. Furney EE: Culture: A Modern Method. St. Louis, MO: Nixon Jones Printing Co;
1890.
2. The Editors, Anon: Dear Doctor. Ciba Symposium 1967, 15:106.
3. Cryan JF, O’Mahony SM: The microbiome-gut-brain axis: from bowel to
behavior. Neurogastroenterol Motil 2011, 23:187–192.
4. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M: Exposure to
a social stressor alters the structure of the intestinal microbiota:
implications for stressor-induced immunomodulation. Brain Behav Immun
2011, 25:397–407.
5. Bailey MT, Dowd SE, Parry NM, Galley JD, Schauer DB, Lyte M: Stressor
exposure disrupts commensal microbial populations in the intestines
and leads to increased colonization by Citrobacter rodentium. Infect
Immun 2010, 78:1509–1519.
6. Garber AK, Lustig RH: Is fast food addictive? Curr Drug Abuse Rev 2011,
4:146–162.
7. Brown K, DeCoffe D, Molcan E, Gibson DL: Diet-induced dysbiosis of the
intestinal microbiota and the effects on immunity and disease. Nutrients
2012, 4:1095–1119.
8. Goehler LE, Park SM, Opitz N, Lyte M, Gaykema RP: Campylobacter jejuni
infection increases anxiety-like behavior in the holeboard: possible
anatomical substrates for viscerosensory modulation of exploratory
behavior. Brain Behav Immun 2008, 22:354–366.
9. Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M: Activation
in vagal afferents and central autonomic pathways: early responses to
intestinal infection with Campylobacter jejuni. Brain Behav Immun 2005,
19:334–344.
10. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y,
Blennerhassett PA, Fahnestock M, Moine D, Berger B, Huizinga JD, Kunze W,
McLean PG, Bergonzelli GE, Collins SM, Verdu EF: The anxiolytic effect of
Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain
communication. Neurogastroenterol Motil 2011, 23:1132–1139.
11. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG,
Bienenstock J, Cryan JF: Ingestion of Lactobacillus strain regulates
emotional behavior and central GABA receptor expression in a mouse
via the vagus nerve. Proc Natl Acad Sci USA 2011, 108:16050–16055.
12. Logan AC, Katzman M: Major depressive disorder: probiotics may be an
adjuvant therapy. Med Hypotheses 2005, 64:533–538.
13. Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C: γ-Aminobutyric
acid production by culturable bacteria from the human intestine. Appl
Microbiol 2012, 113:411–417.
14. Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H:
Relaxation and immunity enhancement effects of gamma-aminobutyric
acid (GABA) administration in humans. Biofactors 2006, 26:201–208.
15. Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P,
Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan WI, Corthesy-Theulaz I,
Cherbut C, Bergonzelli GE, Collins SM: Chronic gastrointestinal
inflammation induces anxiety-like behavior and alters central nervous
system biochemistry in mice. Gastroenterology 2010, 139:2102–2112.
16. Arnold L: Alterations in the endogenous enteric bacterial flora and
microbic permeability of the intestinal wall in relation to the nutritional
and meteorological changes. J Hygiene 1929, 29:82–116.
17. Sutherland J, Miles M, Hedderley D, Li J, Devoy S, Sutton K, Lauren D: In
vitro effects of food extracts on selected probiotic and pathogenic
bacteria. Int J Food Sci Nutr 2009, 60:717–727.
18. Li W, Dowd SE, Scurlock B, Acosta-Martinez V, Lyte M: Memory and
learning behavior in mice is temporally associated with diet-induced
alterations in gut bacteria. Physiol Behav 2009, 96:557–567.
19. Lindeberg S: Paleolithic diets as a model for prevention and treatment of
Western disease. Am J Hum Biol 2012, 24:110–115.
20. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett
P, Macri J, McCoy KD, Verdu EF, Collins SM: The intestinal microbiota affect
central levels of brain-derived neurotropic factor and behavior in mice.
Gastroenterology 2011, 141:599–609.
21. Carvalho BM, Guadagnini D, Tsukumo DM, Schenka AA, Latuf-Filho P,
Vassallo J, Dias JC, Kubota LT, Carvalheira JB, Saad MJ: Modulation of gut
microbiota by antibiotics improves insulin signalling in high-fat fed
mice. Diabetologia 2012, 55:2823–2834.
22. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki
M, Ishihara K, Araki T, Horiguchi J: Minocycline as adjunctive therapy for
patients with unipolar psychotic depression: an open-label study. Prog
Neuropsychopharmacol Biol Psychiatry 2012, 37:222–226.
23. Garrido-Mesa N, Utrilla P, Comalada M, Zorrilla P, Garrido-Mesa J, Zarzuelo A,
Rodríguez-Cabezas ME, Gálvez J: The association of minocycline and the
probiotic Escherichia coli Nissle 1917 results in an additive beneficial
effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol
2011, 82:1891–1900.
24. Rodrigues DM, Sousa AJ, Hawley SP, Vong L, Gareau MG, Kumar SA,
Johnson-Henry KC, Sherman PM: Matrix metalloproteinase 9 contributes
to gut microbe homeostasis in a model of infectious colitis.
BMC Microbiol 2012, 12:105.
25. Mikami Y, Dobschütz EV, Sommer O, Wellner U, Unno M, Hopt U, Keck T:
Matrix metalloproteinase-9 derived from polymorphonuclear neutrophils
increases gut barrier dysfunction and bacterial translocation in rat
severe acute pancreatitis. Surgery 2009, 145:147–156.
26. Munjal C, Tyagi N, Lominadze D, Tyagi SC: Matrix metalloproteinase-9 in
homocysteine-induced intestinal microvascular endothelial paracellular
and transcellular permeability. J Cell Biochem 2012, 113:1159–1169.
27. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C,
Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L,
Merlo-Pich E, Alexander RC, Muglia P: Plasma protein biomarkers for
depression and schizophrenia by multi analyte profiling of case–control
collections. PLoS One 2010, 5:e9166.
28. Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M,
Michalak M, Losy J: Increased serum matrix metalloproteinase-9 (MMP-9)
levels in young patients during bipolar depression. J Affect Disord 2013,
146:286–289.
29. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina
A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M,
Hashimoto K: Decreased serum levels of mature brain-derived
neurotrophic factor (BDNF), but not its precursor proBDNF, in patients
with major depressive disorder. PLoS One 2012, 7:e42676.
30. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, De
Caterina R, Carluccio MA: Mediterranean diet polyphenols reduce
inflammatory angiogenesis through MMP-9 and COX-2 inhibition in
human vascular endothelial cells: a potentially protective mechanism in
atherosclerotic vascular disease and cancer. Arch Biochem Biophys 2012,
527:81–89.
31. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB,
Calignano A, Raso GM, Meli R: Probiotics reduce the inflammatory
response induced by a high-fat diet in the liver of young rats. Nutr 2009,
139:905–911.
32. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G,
Bienenstock J: Inhibitory effects of Lactobacillus reuteri on visceral pain
induced by colorectal distension in Sprague–Dawley rats. Gut 2006,
55:191–196.
33. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF: The probiotic
Bifidobacterium infantis 35624 displays visceral antinociceptive effects in
the rat. Neurogastroenterol Motil 2010, 22:1029–1035.
34. Johnson AC, Greenwood-Van MB, McRorie J: Effects of Bifidobacterium
infantis 35624 on post-inflammatory visceral hypersensitivity in the rat.
Dig Dis Sci 2011, 56:3179–3186.
35. Agostini S, Goubern M, Tondereau V, Salvador-Cartier C, Bezirard V, Lévèque
M, Keränen H, Theodorou V, Bourdu-Naturel S, Goupil-Feuillerat N, Legrain-
Raspaud S, Eutamene H: A marketed fermented dairy product containing
Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and
colonic barrier disruption induced by acute stress in rats.
Neurogastroenterol Motil 2012, 24:376–e172.
36. Ait-Belgnaoui A, Eutamene H, Houdeau E, Bueno L, Fioramonti J, Theodorou
V: Lactobacillus farciminis treatment attenuates stress-induced
overexpression of Fos protein in spinal and supraspinal sites after
colorectal distension in rats. Neurogastroenterol Motil 2009, 21:567–573.
37. Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W,
Mao Y, Wang L, Rochat F, Collins SM: Specific probiotic therapy attenuates
antibiotic induced visceral hypersensitivity in mice. Gut 2006, 55:182–190.
Bested et al. Gut Pathogens 2013, 5:4 Page 10 of 13
http://www.gutpathogens.com/content/5/1/438. Alvarez WC: Origin of the so-called autointoxication symptoms.
JAMA 1919, 72:8–13.
39. Stevens S, Gerlach AL, Cludius B, Silkens A, Craske MG, Hermann C:
Heartbeat perception in social anxiety before and during speech
anticipation. Behav Res Ther 2011, 49:138–143.
40. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S: Altered neuro-endocrine
-immune pathways in the irritable bowel syndrome: the top-down and
the bottom-up model. J Gastroenterol 2012, 47:1177–1185.
41. Furnari M, Savarino E, Bruzzone L, Moscatelli A, Gemignani L, Giannini EG,
Zentilin P, Dulbecco P, Savarino V: Reassessment of the role of methane
production between irritable bowel syndrome and functional
constipation. J Gastrointestin Liver Dis 2012, 2:157–163.
4 2 . B a s s e r iR J ,B a s s e r iB ,P i m e n t e lM ,C h o n gK ,Y o u d i mA ,L o wK ,H w a n gL ,S o f f e rE ,
Chang C, Mathur R: Intestinal methane production in obese individuals is
associated with a higher body mass index. Gastroenterol Hepatol 2012, 8:22–28.
43. Holma R, Korpela R, Sairanen U, Blom M, Rautio M, Poussa T, Saxelin M,
Osterlund P: Colonic methane production modifies gastrointestinal
toxicity associated with adjuvant 5-Fluorouracil chemotherapy for
colorectal cancer. J Clin Gastroenterol 2013, 47:45–51.
44. Pimentel M, Chang C: Inflammation and microflora. Gastroenterol Clin
North Am 2011, 40:69–85.
45. Leiby A, Mehta D, Gopalareddy V, Jackson-Walker S, Horvath K: Bacterial
overgrowth and methane production in children with encopresis.
J Pediatr 2010, 156:766–770.
46. Cayan S, Doruk E, Bozlu M, Duce MN, Ulusoy E, Akbay E: The assessment of
constipation in monosymptomatic primary nocturnal enuresis. Int Urol
Nephrol 2001, 33:513–516.
47. Otu-Bassey IB, Ejezie GC, Epoke J, Useh MF: Enterobiasis and its
relationship with anal itching and enuresis among school-age children
in Calabar, Nigeria. Ann Trop Med Parasitol 2005, 99:611–616.
48. Persico AM, Napolioni V: Urinary p-cresol in autism spectrum disorder.
Neurotoxicol Teratol 2012. In Press.
49. Chen GG, Fiori LM, Moquin L, Gratton A, Mamer O, Mechawar N, Turecki G:
Evidence of altered polyamine concentrations in cerebral cortex of
suicide completers. Neuropsychopharmacology 2010, 35:1477–1484.
50. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia
E: New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 2012,
100:752–774.
51. Tsai YC, Chiu YW, Hung CC, Hwang SJ, Tsai JC, Wang SL, Lin MY, Chen HC:
Association of symptoms of depression with progression of CKD.
Am J Kidney Dis 2012, 60:54–61.
52. Davey A, Elias MF, Robbins MA, Seliger SL, Dore GA: Decline in renal
functioning is associated with longitudinal decline in global cognitive
functioning, abstract reasoning and verbal memory. Nephrol Dial
Transplant 2012:. In Press.
53. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, Yeh LR,
Chen HJ, Lee YJ, Houng JY: Serum levels of total p-cresylsulphate are
associated with angiographic coronary atherosclerosis severity in stable
angina patients with early stage of renal failure. Atherosclerosis 2010,
211:579–583.
54. Massy ZA, Barreto DV, Barreto FC, Vanholder R: Uraemic toxins for
consideration by the cardiologist-Beyond traditional and non-traditional
cardiovascular risk factors. Atherosclerosis 2010, 211:381–383.
55. Pedreañez A, Arcaya JL, Carrizo E, Rincón J, Viera N, Peña C, Vargas R,
Mosquera J: Experimental depression induces renal oxidative stress in
rats. Physiol Behav 2011, 104:1002–1009.
56. Tsurugano S, Nakao M, Takeuchi T, Nomura K, Yano E: Job stress
strengthens the link between metabolic risk factors and renal
dysfunction in adult men. Tohoku J Exp Med 2012, 226:101–108.
57. Niwa T: Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010,
20(5 Suppl):S2–S6.
58. Hsu HJ, Yen CH, Chen CK, Wu IW, Lee CC, Sun CY, Chang SJ, Chou CC,
Hsieh MF, Chen CY, Hsu CY, Tsai CJ, Wu MS: Association between uremic
toxins and depression in patients with chronic kidney disease
undergoing maintenance hemodialysis. Gen Hosp Psychiatry 2012.
In Press.
59. Sandler M, Przyborowska A, Halket J, Watkins P, Glover V, Coates ME:
Urinary but not brain isatin levels are reduced in germ-free rats.
J Neurochem 1991, 57:1074–1075.
60. Medvedev A, Igosheva N, Crumeyrolle-Arias M, Glover V: Isatin: role in
stress and anxiety. Stress 2005, 8:175–183.
61. Singh B, Kumar P, Nagpaul JP, Sharma R, Bansal RC: Effect of
administration of isatin on alkaline phosphatase of various organs of rat.
Indian J Physiol Pharmacol 1978, 22:297–300.
62. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW:
Colonic contribution to uremic solutes. JA mS o cN e p h r o l2011, 22:1769–1776.
63. Vanholder R, Bammens B, De Loor H, Glorieux G, Meijers B, Schepers E,
Massy Z, Evenepoel P: Warning: the unfortunate end of p-cresol as a
uraemic toxin. Nephrol Dial Transplant 2011, 26:1464–1467.
64. Goo YA, Cain K, Jarrett M, Smith L, Voss J, Tolentino E, Tsuji J, Tsai YS,
Panchaud A, Goodlett DR, Shulman RJ, Heitkemper M: Urinary Proteome
Analysis of Irritable Bowel Syndrome (IBS) Symptom Subgroups. J
Proteome Res 2012, 11:5650–5662.
65. Patel KP, Luo FJ, Plummer NS, Hostetter TH, Meyer TW: The production of
p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin
J Am Soc Nephrol 2012, 7:982–988.
66. Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int
2012, 81:949–954.
67. Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L,
Houdeau E, Fioramonti J, Bueno L, Theodorou V: Prevention of gut
leakiness by a probiotic treatment leads to attenuated HPA response to
an acute psychological stress in rats. Psychoneuroendocrinology 2012,
37:1885–1895.
68. Wang Y, Kirpich I, Liu Y, Ma Z, Barve S, McClain CJ, Feng W: Lactobacillus
rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor,
promotes intestinal integrity and ameliorates alcohol-induced liver
injury. Am J Pathol 2011, 179:2866–2875.
69. Wang Y, Li Y, Xie J, Zhang Y, Wang J, Sun X, Zhang H: Protective effects of
probiotic Lactobacillus casei Zhang against endotoxin- and d-
galactosamine-induced liver injury in rats via anti-oxidative and anti-
inflammatory capacities. Int Immunopharmacol 2012, 15:30–37.
70. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG: The probiotic
Bifidobacteria infantis: An assessment of potential antidepressant
properties in the rat. J Psychiatr Res 2008, 43:164–174.
71. Komatsuzaki N, Shima J: Effects of live Lactobacillus paracasei on plasma
lipid concentration in rats fed an ethanol-containing diet. Biosci
Biotechnol Biochem 2012, 76:232–237.
72. Wall R, Marques TM, O’Sullivan O, Ross RP, Shanahan F, Quigley EM, Dinan
TG, Kiely B, Fitzgerald GF, Cotter PD, Fouhy F, Stanton C: Contrasting
effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium
breve DPC 6330 on the composition of murine brain fatty acids and gut
microbiota. Am J Clin Nutr 2012, 95:1278–1287.
73. Girard SA, Bah TM, Kaloustian S, Lada-Moldovan L, Rondeau I, Tompkins TA,
et al: Lactobacillus helveticus and Bifidobacterium longum taken in
combination reduce the apoptosis propensity in the limbic system after
myocardial infarction in a rat model. Br J Nutr 2009, 102:1420–1425.
74. Jung IH, Jung MA, Kim EJ, Han MJ, Kim DH: Lactobacillus pentosus var.
plantarum C29 protects scopolamine-induced memory deficit in mice. J
Appl Microbiol 2012, 113:1498–1506.
75. Tikhonova M, Kulikov AV: Antidepressant-Like Effects of Central BDNF
Administration in Mice of Antidepressant Sensitive Catalepsy (ASC)
Strain. Chin J Physiol 2012, 55:284–293.
76. Eutamene H, Bueno L: Role of probiotics in correcting abnormalities of
colonic flora induced by stress. Gut 2007, 56:1495–1497.
77. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG: Effects of the
probiotic Bifidobacterium infantis in the maternal separation model of
depression. Neuroscience 2010, 170:1179–1188.
78. Singh PK, Chopra K, Kuhad A, Kaur IP: Role of Lactobacillus acidophilus
loaded floating beads in chronic fatigue syndrome: behavioral and
biochemical evidences. Neurogastroenterol Motil 2012, 24:366–e170.
79. Shen Q, Shang N, Pinglan L: In vitro and in vivo antioxidant activity of
Bifidobacterium animalis 01 isolated from centenarians. Curr Microbiol.
In Press.
80. Collins S, Verdu E, Denou E, Bercik P: The role of pathogenic microbes
and commensal bacteria in irritable bowel syndrome. Dig Dis 2009,
27(Suppl 1):85–89.
81. Herpfer I, Katzev M, Feige B, Fiebich BL, Voderholzer U, Lieb K: Effects
of substance P on memory and mood in healthy male subjects.
Hum Psychopharmacol 2007, 22:567–573.
82. Lieb K, Walden J, Grunze H, Fiebich BL, Berger M, Normann C: Serum levels
of substance P and response to antidepressant pharmacotherapy.
Pharmacopsychiatry 2004, 37:238–239.
Bested et al. Gut Pathogens 2013, 5:4 Page 11 of 13
http://www.gutpathogens.com/content/5/1/483. Pertwee RG: Targeting the endocannabinoid system with cannabinoid
receptor agonists: pharmacological strategies and therapeutic
possibilities. Philos Trans R Soc Lond B Biol Sci 2012, 367:3353–3363.
84. Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI: Acute effects of a
selective cannabinoid-2 receptor agonist on neuroinflammation in a
model of traumatic brain injury. J Neurotrauma 2011, 28:973–981.
85. Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach
N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y: Activation
of cannabinoid receptor 2 attenuates leukocyte-endothelial cell
interactions and blood–brain barrier dysfunction under inflammatory
conditions. J Neurosci 2012, 32:4004–4016.
86. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy
C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D,
Colombel JF, Ardid D, Desreumaux P: Lactobacillus acidophilus modulates
intestinal pain and induces opioid and cannabinoid receptors. Nat Med
2007, 13:35–37.
87. Bernardo D, Sánchez B, Al-Hassi HO, Mann ER, Urdaci MC, Knight SC,
Margolles A: Microbiota/host crosstalk biomarkers: regulatory response of
human intestinal dendritic cells exposed to Lactobacillus extracellular
encrypted peptide. PLoS One 2012, 7:e36262.
88. Campana R, Federici S, Ciandrini E, Baffone W: Antagonistic activity of
Lactobacillus acidophilus ATCC 4356 on the growth and adhesion/
invasion characteristics of human Campylobacter jejuni. Curr Microbiol
2012, 64:371–378.
89. Prescott SL: Early-life environmental determinants of allergic diseases
and the wider pandemic of inflammatory noncommunicable diseases.
J Allergy Clin Immunol 2013, 131:23–30.
90. Barouei J, Moussavi M, Hodgson DM: Effect of maternal probiotic
intervention on HPA axis, immunity and gut microbiota in a rat model
of irritable bowel syndrome. PLoS One 2012, 7:e46051.
91. Turck FB: Intestinal venous stasis. NY Med J 1916, 104:1072–1073.
92. Turck FB: The mechanism of intestinal atony in children – etiology and
treatment. NY State J Med 1918, 18:1–6.
93. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG,
Smirnova N, Bergé M, Sulpice T, Lahtinen S, Ouwehand A, Langella P,
Rautonen N, Sansonetti PJ, Burcelin R: Intestinal mucosal adherence and
translocation of commensal bacteria at the early onset of type 2
diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med
2011, 3:559–572.
94. Rook GA, Raison CL, Lowry CA: Can we vaccinate against depression?
Drug Discov Today 2012, 17:451–458.
95. O’Brien ME, Anderson H, Kaukel E, O’Byrne K, Pawlicki M, Von Pawel J, et al:
SRL172 (killed Mycobacterium vaccae) in addition to standard
chemotherapy improves quality of life without affecting survival, in
patients with advanced non-small-cell lung cancer: phase III results.
Ann Oncol 2004, 15:906–914.
96. Satterlee GR, Eldridge WW: Symptomatology of the nervous system in
chronic intestinal toxemia. JAMA 1917, 69:1414–1418.
97. Heinemann PG, Hefferan M: A study of Bacillus Bulgaricus. J Infect Dis
1909, 6:304–318.
98. Teixeira LC, Peixoto RS, Cury JC, Sul WJ, Pellizari VH, Tiedje J, Rosado AS:
Bacterial diversity in rhizosphere soil from Antarctic vascular plants of
Admiralty Bay, maritime Antarctica. ISME J 2010, 4:989–1001.
99. Matthews DM, Jenks SM: Effect of Mycobacterium vaccae on learning in mice,
Proceedings of the American Society for Microbiology 110th General
Meeting. San Diego, California: Poster 641; 2010.
100. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi
M, Mofid V: Probiotic yogurt improves antioxidant status in type 2
diabetic patients. Nutrition 2012, 28:539–543.
101. Martarelli D, Verdenelli MC, Scuri S, Cocchioni M, Silvi S, Cecchini C, Pompei
P: Effect of a probiotic intake on oxidant and antioxidant parameters in
plasma of athletes during intense exercise training. Curr Microbiol 2011,
62:1689–1696.
102. Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P: Does glycemic
variability impact mood and quality of life? Diabetes Technol Ther 2012,
14:303–310.
103. Soifer LO, Peralta D, Dima G, Besasso H: Comparative clinical efficacy
of a probiotic vs. an antibiotic in the treatment of patients with
intestinal bacterial overgrowth and chronic abdominal functional
distension: a pilot study. Acta Gastroenterol Latinoam 2010,
40:323–327.
104. Tillisch K, Labus JS, Ebrat B, Stains J, Naliboff B, Guyonnet D, Legrain-
Raspaud S, Trotin B, Mayer EA: Modulation of the brain-gut axis after
4-week intervention with a probiotic fermented dairy product.
Gastroenterology 2012, 142(Suppl 1):S-115.
105. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF,
Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A,
Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes
ES, De Vos WM, Hoekstra JB, Nieuwdorp M: Transfer of intestinal
microbiota from lean donors increases insulin sensitivity in individuals
with metabolic syndrome. Gastroenterology 2012, 143:913–916. e7.
106. Borody T, Leis S, Campbell J, Torres M, Nowak A: Fecal microbiota
transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol 2011,
106:S352.
107. Fei N, Zhao L: An opportunistic pathogen isolated from the gut of an
obese human causes obesity in germfree mice. ISME J 2012, 2012:2012.
In Press.
108. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S,
Stronati L: Randomised clinical trial: the effectiveness of Lactobacillus
reuteri ATCC 55730 rectal enema in children with active distal ulcerative
colitis. Aliment Pharmacol Ther 2012, 35:327–334.
109. Audy EO, Claud EC, Gloor GB, Allen-Vercoe E: Microbial ecosystems
therapeutics: a new paradigm in medicine? Benef Microbes 2012, 1:1–13.
110. Bercik P, Collins SM, Verdu EF: Microbes and the gut-brain axis.
Neurogastroenterol Motil 2012, 24:405–413.
111. Benton D, Williams C, Brown A: Impact of consuming a milk drink
containing a probiotic on mood and cognition. Eur J Clin Nutr 2007,
61:355–361.
112. Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, et al:
A randomized, double-blind, placebo-controlled pilot study of a
probiotic in emotional symptoms of chronic fatigue syndrome.
Gut Pathog 2009, 1:6.
113. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al:
Assessment of psychotropic-like properties of a probiotic formulation
(Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in
rats and human subjects. Br J Nutr 2011, 105:755–764.
114. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C: Beneficial
psychological effects of a probiotic formulation (Lactobacillus helveticus
R0052 and Bifidobacterium longum R0175) in healthy human
volunteers. Gut Microbes 2011, 2:256–261.
115. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR: Clinical trial: the effects of
a trans-galactooligosaccharide prebiotic on faecal microbiota and
symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009,
29:508–518.
116. Galdston I: On the futility of medical history. Can Med Assoc J 1965,
93:807–811.
117. Maes M, Twisk F: Chronic fatigue syndrome: Harvey and Wessely’s (bio)
psychosocial model versus a bio(psychosocial) model based on
inflammatory and oxidative and nitrosative stress pathways. BMC Med
2010, 8:35.
118. Wessely S: Surgery for the treatment of psychiatric illness: the need to
test untested theories. J R Soc Med 2009, 102:445–451.
119. Tayama J, Nakaya N, Hamaguchi T, Tomiie T, Shinozaki M, Saigo T, Shirabe S,
Fukudo S: Effects of personality traits on the manifestations of irritable
bowel syndrome. Biopsychosoc Med 2012, 6:20.
120. Galdston I: The Roots of Psychosomatic Medicine. Can Med Assoc J 1954,
70:127–132.
121. Froberg-Fejko KM, Lecker JL: Going back to nature: the benefits of wood
enrichment. Lab Anim 2012, 41:346–347.
122. Matsumoto M, Inoue R, Tsukahara T, Ushida K, Chiji H, Matsubara N, Hara H:
Voluntary running exercise alters microbiota composition and increases
n-butyrate concentration in the rat cecum. Biosci Biotechnol Biochem 2008,
72:572–576.
123. Medina S, Domínguez-Perles R, García-Viguera C, Cejuela-Anta R, Martínez-
Sanz JM, Ferreres F, Gil-Izquierdo A: Physical activity increases the
bioavailability of flavanones after dietary aronia-citrus juice intake in
triathletes. Food Chem 2012, 135:2133–2137.
124. Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Asada M, Watanabe K,
Hayashida N, Ihara M, Ito H, Shimohama S, Kihara T, Kinoshita A:
Environmental enrichment ameliorated high-fat diet-induced Aβ
deposition and memory deficit in APP transgenic mice. Neurobiol Aging
2012, 33:1011. e11-23.
Bested et al. Gut Pathogens 2013, 5:4 Page 12 of 13
http://www.gutpathogens.com/content/5/1/4125. Suzuki C, Kimoto-Nira H, Kobayashi M, Nomura M, Sasaki K, Mizumachi K:
Immunomodulatory and cytotoxic effects of various Lactococcus strains
on the murine macrophage cell line J774.1. Int J Food Microbiol 2008,
123:159–165.
126. Di Cagno R, Minervini G, Sgarbi E, Lazzi C, Bernini V, Neviani E, Gobbetti M:
Comparison of phenotypic (Biolog System) and genotypic (random
amplified polymorphic DNA-polymerase chain reaction, RAPD-PCR, and
amplified fragment length polymorphism, AFLP) methods for typing
Lactobacillus plantarum isolates from raw vegetables and fruits.
Int J Food Microbiol 2010, 143:246–253.
127. Abou-Donia MB, El-Masry EM, Abdel-Rahman AA, McLendon RE, Schiffman
SS: Splenda alters gut microflora and increases intestinal p-glycoprotein
and cytochrome p-450 in male rats. J Toxicol Environ Health A 2008,
71:1415–1429.
128. Mueller F: Yoghurt: The Bulgarian national dish, the anti-toxin for old
age. Health Culture 1913, 19:295.
129. Wright C: Forget prozac, try probiotics. The Natural News 2012 .
130. Specter M: Germs are us. The New Yorker 2012, 88(Oct 22):32–39.
131. Matsumoto M, Kurihara S, Kibe R, Ashida H, Benno Y: Longevity in mice is
promoted by probiotic-induced suppression of colonic senescence
dependent on upregulation of gut bacterial polyamine production.
PLoS One 2011, 6:e23652.
132. Altmaier E, Emeny RT, Krumsiek J, Lacruz ME, Lukaschek K, Häfner S,
Kastenmüller G, Römisch-Margl W, Prehn C, Mohney RP, Evans AM, Milburn
MV, Illig T, Adamski J, Theis F, Suhre K, Ladwig KH: Psychoneuroendocrinology
2012. In Press.
doi:10.1186/1757-4749-5-4
Cite this article as: Bested et al.: Intestinal microbiota, probiotics and
mental health: from Metchnikoff to modern advances:
part III – convergence toward clinical trials. Gut Pathogens 2013 5:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bested et al. Gut Pathogens 2013, 5:4 Page 13 of 13
http://www.gutpathogens.com/content/5/1/4